Ardelyx (ARDX) Expected to Announce Earnings on Thursday

Ardelyx (NASDAQ:ARDX - Get Free Report) is expected to announce its Q1 2025 earnings results after the market closes on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $79.40 million for the quarter.

Ardelyx (NASDAQ:ARDX - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.02 EPS for the quarter, hitting analysts' consensus estimates of $0.02. Ardelyx had a negative return on equity of 24.87% and a negative net margin of 11.73%. The firm had revenue of $116.13 million during the quarter, compared to analyst estimates of $111.16 million. On average, analysts expect Ardelyx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ardelyx Stock Performance

Shares of NASDAQ:ARDX traded up $0.24 during midday trading on Friday, reaching $5.26. 4,562,725 shares of the company traded hands, compared to its average volume of 4,373,915. The firm's fifty day moving average price is $5.04 and its two-hundred day moving average price is $5.28. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of -32.88 and a beta of 0.81. The company has a quick ratio of 4.31, a current ratio of 4.58 and a debt-to-equity ratio of 0.87. Ardelyx has a 12 month low of $4.02 and a 12 month high of $9.33.

Analysts Set New Price Targets

ARDX has been the topic of a number of recent analyst reports. Piper Sandler raised shares of Ardelyx to a "hold" rating in a report on Wednesday, March 12th. Jefferies Financial Group cut their price target on shares of Ardelyx from $11.00 to $8.00 and set a "buy" rating for the company in a report on Thursday, January 2nd. LADENBURG THALM/SH SH reaffirmed a "buy" rating and issued a $11.00 price target on shares of Ardelyx in a report on Friday, March 7th. Scotiabank began coverage on Ardelyx in a research note on Friday, March 7th. They set a "sector outperform" rating and a $15.00 price objective for the company. Finally, Cantor Fitzgerald upgraded Ardelyx to a "strong-buy" rating in a research note on Tuesday, March 4th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Ardelyx has a consensus rating of "Moderate Buy" and a consensus target price of $10.61.

Insider Activity at Ardelyx

In related news, CEO Michael Raab sold 41,666 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $5.36, for a total transaction of $223,329.76. Following the completion of the sale, the chief executive officer now directly owns 1,108,719 shares in the company, valued at $5,942,733.84. This represents a 3.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director David M. Mott purchased 77,729 shares of Ardelyx stock in a transaction that occurred on Monday, February 24th. The shares were bought at an average price of $5.00 per share, for a total transaction of $388,645.00. Following the completion of the transaction, the director now owns 2,015,494 shares in the company, valued at $10,077,470. The trade was a 4.01 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have sold 158,076 shares of company stock valued at $823,804. Corporate insiders own 5.90% of the company's stock.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.